Document Detail


Reduced neutrophil superoxide anion release after prolonged infusions of lidocaine.
MedLine Citation:
PMID:  2997433     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lidocaine is used extensively in coronary care units, yet the effect of lidocaine infusions on neutrophil function has not been known. Lidocaine and other local anesthetics impair leukocyte antibacterial functions when added in vitro. We found that lidocaine added to human neutrophils in vitro markedly impaired the release of superoxide anion (O2-) and the granule enzymes lysozyme and myeloperoxidase after stimulation by phorbol myristate acetate or opsonized zymosan. We then measured production of O2- during stimulation of neutrophils from eight normal subjects, five coronary artery disease patients not receiving lidocaine and 13 coronary artery disease patients receiving lidocaine infusions for at least 12 hr. Release of O2- by cells from lidocaine-treated patients (14.2 +/- 3.8 nmol/2.5 X 10(6) neutrophils per 15 min) was significantly lower than from cells of the normal subjects (78.4 +/- 7.2 nmol; P less than .001) and the coronary patients not receiving lidocaine (70.6 +/- 4.0 nmol; P less than .001). Bactericidal assays at a high concentration (2 mg/ml) of lidocaine demonstrated slight reductions in 2 hr killing rates for Escherichia coli (70% with lidocaine vs. 95% control). Inhibition by lidocaine of the release of toxic oxygen metabolites from neutrophils could potentially reduce infarct size in patients with acute myocardial infarction; but as there is only a slightly reduced ability to kill bacteria, increased susceptibility to infections is unlikely although it cannot be excluded.
Authors:
S L Peck; R B Johnston; L D Horwitz
Related Documents :
22623413 - Pharmacologically dosed oral glutamine reduces myocardial injury in patients undergoing...
2936533 - Effect of propranolol on myocardial ischemia occurring during acute coronary occlusion.
11924703 - Tunel: a useful screening method in sudden cardiac death.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  235     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  1985 Nov 
Date Detail:
Created Date:  1985-12-20     Completed Date:  1985-12-20     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  418-22     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Bactericidal Activity
Humans
Lidocaine / adverse effects*
Luminescent Measurements
Lysosomes / enzymology
Muramidase / blood
Neutrophils / drug effects,  metabolism*
Peroxidase / blood
Phagocytosis
Superoxides / blood*
Tetradecanoylphorbol Acetate / pharmacology
Time Factors
Zymosan / pharmacology
Grant Support
ID/Acronym/Agency:
AI 14148/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
11062-77-4/Superoxides; 137-58-6/Lidocaine; 16561-29-8/Tetradecanoylphorbol Acetate; 9010-72-4/Zymosan; EC 1.11.1.7/Peroxidase; EC 3.2.1.17/Muramidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Receptors for opioid peptides in the guinea-pig ileum.
Next Document:  Synaptic facilitation by 3-aminopyridine and its antagonism by verapamil and diltiazem.